KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

BioNTech SE (BNTX) EBITDA: 2017-2024

Historic EBITDA for BioNTech SE (BNTX) over the last 8 years, with Dec 2024 value amounting to -$1.4 billion.

  • BioNTech SE's EBITDA fell 129.06% to -$59.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 billion, marking a year-over-year increase of 8.25%. This contributed to the annual value of -$1.4 billion for FY2024, which is 289.07% down from last year.
  • Per BioNTech SE's latest filing, its EBITDA stood at -$1.4 billion for FY2024, which was down 289.07% from $742.8 million recorded in FY2023.
  • BioNTech SE's EBITDA's 5-year high stood at $17.5 billion during FY2021, with a 5-year trough of -$1.4 billion in FY2024.
  • Its 3-year average for EBITDA is $4.1 billion, with a median of $742.8 million in 2023.
  • As far as peak fluctuations go, BioNTech SE's EBITDA soared by 17,896.61% in 2021, and later tumbled by 289.07% in 2024.
  • Yearly analysis of 5 years shows BioNTech SE's EBITDA stood at -$98.2 million in 2020, then spiked by 17,896.61% to $17.5 billion in 2021, then dropped by 26.23% to $12.9 billion in 2022, then crashed by 94.24% to $742.8 million in 2023, then slumped by 289.07% to -$1.4 billion in 2024.